西 妥珠单抗
单克 | |
---|---|
种类 | ? |
ROR1 | |
其他 | UC-961 |
| |
识别 | |
CAS | 1643432-38-5 |
UNII |
它是
参考 资料
[编辑]- ^ Choi MY, Widhopf GF, Castro J, Li H, Kidwell RL, Zhang SC, et al. Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts. Blood. 2015, 126 (23): 1736 [2024-03-10]. doi:10.1182/blood.V126.23.1736.1736. (
原始 内容 存 档于2019-09-13). - ^ Researchers to test novel drug combination against toughest breast cancers. Medical Express. 2018-08-27 [2024-03-10]. (
原始 内容 存 档于2023-04-06). - ^ Clinical trial number NCT03420183 for "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies" at ClinicalTrials.gov
- ^ 1st Mantle Cell Lymphoma Patient Dosed in Phase 1/2 Trial Testing Cirmtuzumab-Imbruvica Combo. Lymphoma News Today. 2018-05-18 [2024-03-10]. (
原始 内容 存 档于2023-04-07).